Injectable Sustained Release Pharmaceutical Composition Patent

ChangeBridge: EPO Bulletin - Medical Devices (A61M)

Published March 25th, 2026

Detected April 1st, 2026

Summary

The European Patent Office published Patent EP4436633A1 for SpecGx LLC, covering an injectable sustained release pharmaceutical composition. The patent lists inventors Mark Worley and William Sanders with IPC classifications in A61K (pharmaceutical preparations) and A61M (medical devices for injections). The patent designates 31 European member states and extension states.

View original document View source feed page

What changed

The EPO granted Patent EP4436633A1 to SpecGx LLC for an injectable sustained release pharmaceutical composition. The invention is classified under IPC codes A61K 9/00, A61M 5/178, A61M 5/32, and A61K 38/00, indicating drug delivery technology combining pharmaceutical formulations with injection device innovations. The patent was published on March 25, 2026.

This patent publication is informational for compliance purposes. Pharmaceutical companies developing sustained release injectable formulations should review the patent claims to assess potential licensing needs or design-around opportunities. No immediate compliance action is required; however, legal teams monitoring intellectual property in the drug delivery space should catalog this patent for freedom-to-operate analysis on related products.

Source document (simplified)

← EPO Patent Bulletin

INJECTABLE SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION

Publication EP4436633A1 Kind: A1 Mar 25, 2026

Applicants

SpecGx LLC

Inventors

WORLEY, Mark, SANDERS, William

IPC Classifications

A61K 9/00 20060101AFI20250903BHEP A61M 5/178 20060101ALI20250903BHEP A61M 5/32 20060101ALI20250903BHEP A61K 38/00 20060101ALI20250903BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →